<p><h1>Opioid-induced Constipation Market Research Report Unlocks Analysis on the Market Financial Status, Market Size, and Market Revenue upto 2031</h1></p><p><strong>Opioid-induced Constipation Market Analysis and Latest Trends</strong></p>
<p><p>Opioid-induced constipation (OIC) is a common side effect that occurs when individuals use opioid medications for pain management. Opioids, such as morphine, codeine, and oxycodone, are powerful pain relievers that can cause the muscles in the digestive tract to slow down. This leads to constipation, which can be uncomfortable and impact the quality of life for patients.</p><p>The opioid-induced constipation market has been steadily growing in recent years, primarily due to the rising prevalence of chronic pain conditions and the increasing use of opioid medications. According to market research, the market is expected to grow at a compound annual growth rate (CAGR) of 14.4% during the forecast period.</p><p>Several factors are driving the growth of the opioid-induced constipation market. Firstly, there is a growing demand for effective and safe opioid-induced constipation treatments that can alleviate symptoms without interfering with the pain-relieving benefits of opioids. Pharmaceutical companies are developing novel drugs and therapies specifically targeted to treat OIC.</p><p>In addition, there is an increasing awareness among healthcare providers about the prevalence of OIC and the need for early intervention. This is leading to better diagnosis and management of OIC in patients who are prescribed opioids for pain management.</p><p>Furthermore, the aging population and the growing number of individuals suffering from chronic pain conditions are further contributing to the growth of the opioid-induced constipation market.</p><p>Overall, with the increasing prevalence of OIC and the rising demand for effective treatment options, the opioid-induced constipation market is expected to witness significant growth in the coming years.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1012595">https://www.reliableresearchreports.com/enquiry/request-sample/1012595</a></p>
<p>&nbsp;</p>
<p><strong>Opioid-induced Constipation Major Market Players</strong></p>
<p><p>The opioid-induced constipation (OIC) market is highly competitive, with several players striving to capture a significant market share. Some key players in this market include AstraZeneca, Takeda Pharmaceutical, Bausch Health, Abbott, Bayer, Boehringer Ingelheim, C.B. Fleet, Cosmo Pharmaceuticals, Daewoong, Daiichi Sankyo, GlaxoSmithKline, Ironwood Pharmaceuticals, Johnson and Johnson, Merck, Mundipharma, Nektar Therapeutics, Pfizer, Progenics Pharmaceuticals, Shionogi, SLA Pharma, Sucampo, Synergy Pharmaceuticals, and Theravance.</p><p>AstraZeneca, a leading pharmaceutical company, has a strong presence in the OIC market. Its product Movantik (naloxegol) has shown significant growth in recent years. In 2018, Movantik generated sales revenue of approximately $281 million. AstraZeneca aims to further expand its market share by focusing on marketing strategies and expanding its product portfolio.</p><p>Takeda Pharmaceutical is another key player in the market, with its product Entereg (alvimopan). In 2018, Takeda reported sales revenue of around $386 million from Entereg. Takeda is actively investing in research and development to develop novel therapies for OIC, which indicates its commitment to the future growth of this market.</p><p>Bausch Health, formerly known as Valeant Pharmaceuticals, has a notable presence in the OIC market with its product Relistor (methylnaltrexone). In 2018, Relistor generated sales revenue of approximately $282 million. Bausch Health is focusing on expanding its market share through strategic partnerships and collaborations.</p><p>Ironwood Pharmaceuticals, in collaboration with Allergan, developed Linzess (linaclotide), which is approved for the treatment of chronic idiopathic constipation (CIC). Linzess has shown potential for the treatment of OIC as well. In 2018, Ironwood reported sales revenue of approximately $600 million from Linzess.</p><p>Johnson and Johnson's product, Movantik (naloxegol), has significant market presence and has reported sales revenue of around $234 million in 2018. Johnson and Johnson is investing in research and development to explore additional indications for Movantik, which indicates its focus on future market growth.</p><p>Overall, the opioid-induced constipation market is witnessing substantial growth, driven by the increasing use of opioids for pain management. The market is expected to grow further in the coming years, as pharmaceutical companies invest in research and development to develop innovative treatments for OIC. The market size is anticipated to reach several billion dollars by 2026, presenting lucrative opportunities for both existing and new players in this competitive landscape.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Opioid-induced Constipation Manufacturers?</strong></p>
<p><p>The opioid-induced constipation market has been witnessing significant growth due to the increasing use of opioids for pain management. Opioids act on the central nervous system, slowing down bowel movements and leading to constipation. This has resulted in the development of advanced medications specifically targeted at treating opioid-induced constipation. With the rising prevalence of chronic pain and increased opioid use, the market is expected to experience steady growth over the forecast period. Moreover, advancements in medical technology and the introduction of novel treatment options are likely to further drive market growth in the future.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1012595">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1012595</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Opioid-induced Constipation Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Solid</li><li>Liquid</li></ul></p>
<p><p>Opioid-induced constipation (OIC) market has two types: solid and liquid market. In the solid market, pharmaceutical companies develop oral tablets or capsules to address OIC. These medications are designed to stimulate bowel movements and provide relief from constipation caused by opioid use. In the liquid market, companies develop oral solutions or suspensions that can be ingested to treat OIC. These liquid formulations aim to provide a more convenient and alternative option for individuals experiencing constipation due to opioids. Both solid and liquid markets cater to the specific needs of OIC patients.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1012595">https://www.reliableresearchreports.com/purchase/1012595</a></p>
<p>&nbsp;</p>
<p><strong>The Opioid-induced Constipation Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Drugstore</li><li>Hospital</li><li>Others</li></ul></p>
<p><p>The opioid-induced constipation market entails the application of treatments for constipation caused by opioid use. Drugstores play a significant role in this market as they dispense medications like laxatives and prescription drugs. Hospitals cater to patients requiring immediate medical intervention for severe constipation. Other market participants may include specialty clinics and rehabilitation centers offering opioid dependency treatment. All these places serve as crucial channels for accessing medications, therapies, and healthcare services specifically designed to address opioid-induced constipation, thereby helping patients manage this common side effect of opioid therapy.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Opioid-induced Constipation Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The opioid-induced constipation market is anticipated to witness significant growth across various regions, including North America (NA), Asia-Pacific (APAC), Europe, the United States of America (USA), and China. North America is projected to dominate the market, holding the largest market share percent valuation. This can be attributed to the high prevalence of opioid use and the widespread awareness of effective constipation treatment options in the region. Additionally, factors such as increasing healthcare expenditure, developed healthcare infrastructure, and rising patient focus towards enhanced quality of life are expected to drive market growth in North America.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1012595">https://www.reliableresearchreports.com/purchase/1012595</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1012595">https://www.reliableresearchreports.com/enquiry/request-sample/1012595</a></p>
<p><strong></strong></p>
<p><p><a href="https://github.com/dzharov81/Market-Research-Report-List-2/blob/main/human-microbiome-market.md">Human Microbiome Market</a></p></p>